Breaking News, Collaborations & Alliances

Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies

Aim to develop and commercialize RGX-121 and RGX-111 for MPS diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Regenxbio Inc. and Nippon Shinyaku Co., Ltd. have entered a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for Mucopolysaccharidosis I (MPS I), also known as Hurler syndrome. Under the terms of the agreement, Regenxbio will receive $110 million at closing and up to an additional $700 million if certain milestones are achieved, consisting of $40 million in potential de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters